Lista de obras -

A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein

artículo científico publicado en 2007

Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein

artículo científico publicado en 2004

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines

artículo científico publicado en 2006

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice

artículo científico publicado en 2009

Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo

artículo científico publicado en 2004

Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation

artículo científico publicado en 2009

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

artículo científico publicado en 2009

Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment

artículo científico publicado en 2006

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

artículo científico publicado en 2008

Molecular mechanism of paramyxovirus budding

artículo científico publicado en 2004

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site

artículo científico publicado en 2010

Nontypeable Haemophilus influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein

artículo científico publicado en 2007

Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion.

artículo científico publicado en 2002

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein ⬇️

artículo científico publicado el 16 de agosto de 2011

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus

artículo científico publicado en 2005

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

artículo científico publicado en 2004

Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice

artículo científico publicado en 2009

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

artículo científico publicado en 2007

Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion

artículo científico publicado en 2002

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children

artículo científico publicado en 2014

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

artículo científico publicado en 2020

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

artículo científico publicado en 2004

Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion

artículo científico publicado en 2004

Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats

artículo científico publicado en 2014

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

scientific article published on May 2008

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection ⬇️

artículo científico publicado el 23 de noviembre de 2011

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

artículo científico publicado en 2014

Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus

artículo científico publicado en 2006

Structure, Function, and Intracellular Processing of the Glycoproteins of Paramyxoviridae

artículo científico publicado en 1991

The long noncoding region of the human parainfluenza virus type 1 f gene contributes to the read-through transcription at the m-f gene junction

artículo científico publicado en 2002

The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae

artículo científico publicado en 2005

Lista de obras de

A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein

Biological significance of the second receptor binding site of Newcastle disease virus hemagglutinin-neuraminidase protein

Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice

Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo

Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Molecular mechanism of paramyxovirus budding

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site

Nontypeable Haemophilus influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein

Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle disease virus: identification of key amino acids involved in cell binding, catalysis, and fusion.

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein ⬇️

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion

Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion

Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection ⬇️

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

Structural analysis of a designed inhibitor complexed with the hemagglutinin-neuraminidase of Newcastle disease virus

Structure, Function, and Intracellular Processing of the Glycoproteins of Paramyxoviridae

The long noncoding region of the human parainfluenza virus type 1 f gene contributes to the read-through transcription at the m-f gene junction

The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae